

# Claims-based Algorithms to Identify Persons with Severe Hemophilia A

Khairnar R<sup>1</sup>, Mahajerin A<sup>2</sup>, Shapiro A<sup>3</sup>, Sidonio R<sup>4</sup>, Okolo A<sup>3</sup>, Decker-Palmer M<sup>1</sup>, Patel AM<sup>1</sup>, Gibbs SN<sup>5</sup>, Campos C<sup>5</sup>, Broder MS<sup>5</sup>, Yermilov I<sup>5</sup>



## Summary


ICD-10 diagnosis codes for hemophilia A do not differentiate by disease severity.



We developed claims-based algorithms to identify persons with severe hemophilia A among those with hemophilia A.



We conducted a retrospective review of medical records to test algorithm performance.



The algorithm with hemophilia A treatments demonstrated satisfactory performance, increasing confidence in its ability to identify patients with severe hemophilia A in healthcare claims.

<sup>1</sup>Genentech – A Member of the Roche Group, South San Francisco, CA, USA

<sup>2</sup>Children's Hospital of Orange County, Orange, CA, USA

<sup>3</sup>Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA

<sup>4</sup>Children's Healthcare of Atlanta, Emory University, Atlanta, GA, USA

<sup>5</sup>Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA



## Background & Objective

- Hemophilia A is an inherited deficiency of clotting Factor VIII that impairs hemostasis and coagulation ability, resulting in excessive musculoskeletal bleeding. It is characterized as severe, moderate, or mild based on level of Factor VIII activity.
- ICD-10 diagnosis codes for hemophilia A do not differentiate by disease severity.
- Compared to less severe patients, those with severe hemophilia A experience differences in disease burden, resource use, and outcomes. Being able to identify patients by disease severity in a large population using healthcare claims data would improve estimates of disease burden and healthcare utilization.
- Particularly when studying rare diseases, use of algorithms that don't accurately identify the population of interest can lead to misclassification bias and incorrect estimation of incidence and health services utilization (Benchimol J Clin Epi 2011).
- We aimed to develop and test claims-based algorithms to identify persons with severe hemophilia A among those with hemophilia A.

## Methods

- Conducted a retrospective review of medical records of a purposive sample of 100 male patients with hemophilia A (53 severe, 47 not severe) without von Willebrand disease at 4 geographically dispersed treatment centers in the United States from 01/2020-07/2021.
- Used cognitive interviews with 4 physicians to develop variables that 1) could be used in healthcare claims and 2) could identify patients with severe hemophilia A. Physician verified diagnosis of hemophilia A severity was considered the gold standard.
  - Variables were grouped into distinct concept groups: symptoms of hemophilia A, treatment of symptoms, treatments of hemophilia A, and side-effects of treatments (Table 1).
- Tested the variable performance.
  - Calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for each variable.
  - Calculated pairwise correlations for each variable pair within the concept groups.
  - The higher performing variable in pairs with high correlation, defined as  $|r| \geq 0.5$ , remained in the concept group.
- Concept groups were tested individually and in combination to identify algorithms with high sensitivity, specificity, PPV, and NPV. The use of intravenous or intranasal desmopressin (DDAVP) was incorporated in all concept groups testing.
- Patient weight, which is unavailable in healthcare claims, was collected and compared to expected weights based on CDC's weight for age tables.
- To account for the evolving treatment landscape, separate algorithms with or without hemophilia A treatment were identified.

Table 1. Concept Groups and Variables

Concept Group Name	Variables <sup>1</sup>
Symptoms of hemophilia	<ul style="list-style-type: none"> <li><math>\geq 1</math> non-traumatic intracranial hemorrhage (age <math>\leq 60</math> years<sup>2</sup>)</li> <li><math>\geq 2</math> diagnoses of arthropathy per year (age <math>\leq 35</math> years<sup>2</sup> or any age)</li> <li><math>\geq 2</math> diagnoses of hemarthrosis per year</li> </ul>
Treatments for symptoms of hemophilia	<ul style="list-style-type: none"> <li><math>\geq 2</math> joint replacements/fusions (age <math>\leq 40</math> years<sup>2</sup> or any age)</li> <li><math>\geq 1</math> joint replacement/fusion (age <math>\leq 40</math> years<sup>2</sup>)</li> <li><math>\geq 10</math> physical therapy visits per year</li> <li><math>\geq 90</math>-day supply of opioids per 6-month period (age <math>\leq 40</math> years<sup>2</sup>)</li> <li><math>\geq 2</math> prescriptions for a COX-2 inhibitor per year</li> </ul>
Treatments of hemophilia	<ul style="list-style-type: none"> <li>Evidence of prophylaxis – high (at least 50 units of Factor VIII/kg per week for 45 weeks in 1 year)</li> <li>Evidence of prophylaxis – low (at least 50 units of Factor VIII/kg per week for 22 weeks in 6 months)</li> <li><math>\geq 1</math> prescription for emicizumab</li> <li><math>\geq 1</math> central line procedure</li> </ul>
Side effects of treatments	<ul style="list-style-type: none"> <li>Evidence of inhibitors (operationalized as <math>\geq 1</math> prescription for a bypassing agent)</li> </ul>

<sup>1</sup>All variables were originally included for correlation testing. After testing, variables in blue were removed from concept groups.

<sup>2</sup>Age cut offs were determined with clinical input based on when that variable would be more likely to identify severe hemophilia than another condition (e.g., joint replacements due to hemarthrosis rather than advancing age).

## Limitations

- Included a small and purposive sample of patients, which may not be representative of the general population and may have artificially decreased algorithm performance.
- Clinic medical records are incomplete. Hospitalizations, procedures, and home bleeding episodes may not have been thoroughly documented.
- Assumed that the data abstracted from medical records is represented in healthcare claims but did not validate algorithms in the full healthcare claims records of the included study patients.

## References

- Benchimol EI, Manuel DG, To T, Griffiths AM, Rabeneck L, Guttmann A. Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data. *J Clin Epidemiol.* 2011 Aug;64(8):821-9. doi: 10.1016/j.jclinepi.2010.10.006.

## Funding

This study was funded by Genentech, Inc.

## Disclosures

RK, AP, and MDP are employees of Genentech, Inc. AM has received consulting fees and speaker's fees from Alexion, Apellis, Genentech, Inc. and Spark Therapeutics. ADS is an employee of Indiana Hemophilia and Thrombosis Center, Inc.; has received consultancy fees from Sangamo Biosciences, Prometic Life Sciences, and Sigilon; research funding from Bioverativ, Sanofi, Genentech, Inc., Kedron Biopharma, Novo Nordisk, Pfizer, Sigilon, Takeda, Prometic Life Sciences, and Freeline; Honoraria from Genentech, Inc., Sigilon, Novo Nordisk, and Pfizer, and Catalyst Biosciences; Speaker's bureau for Genentech, Inc. and Novo Nordisk; and has held membership on an entity's Board of Directors or advisory committees for Novo Nordisk Hemophilia Foundation, Genentech, Inc., Sigilon, Novo Nordisk, and Sanofi. AO declares no conflict of interest. RS has received honoraria for consulting from Takeda, Unigene, Genentech/Roche, Octapharma, Hema Biologics, Bayer, Guardian Therapeutics, Biand Therapeutics, Novo Nordisk, and Sanofi/Sobi, and has investigator-initiated grant funding for ATHN 9 (Takeda), MOTIVATE study (Octapharma), FEIBA SAFE study (Takeda), and Emi PUPs and Nuwiq ITI study (Octapharma and Genentech). SNG, CC, MSB, IY are employees of PHAR, LLC, which was paid by Genentech to conduct the research reported in this abstract and has received funding from the following entities for research unrelated to the work described in this abstract: AbbVie, Amgen, AstraZeneca, BioMarin Pharmaceuticals, BMS, Celgene, Dompe, Eisai, Exact Sciences Corporation, GRAIL, Jazz, Kite, Novartis, Otsuka, Recordati, Regeneron, Sanofi, and Takeda Pharmaceuticals USA.

## Results Study Sample

- Mean age of the sample was 27.7 years and was similar among patients with mild/moderate and severe disease (Table 2).
- Average weight for both groups was similar, both when using weights reported in medical charts (mild/moderate 70.9kg; severe 67.3kg) and expected weights based on age (mild/moderate 65.5kg; severe 68.8kg).
- Mean follow up was approximately 2.5 years (899 days).

Table 2. Study Sample

	All Patients	Mild/Moderate Hemophilia A	Severe Hemophilia A
Number of patients, %	100	47 (47%)	53 (53%)
Mean age in years at last clinic visit (SD)	27.7 (19.6)	28.2 (21.3)	27.3 (18.1)
Mean weight in kg reported in medical charts (SD)	69.0 (27.6)	70.9 (30.8)	67.3 (24.5)
Mean weight in kg expected based on age (SD)	67.3 (25.0)	65.5 (26.1)	68.8 (24.1)
Mean study period (follow-up), days (SD) [median]	899 (174.1) [824.0]	926 (172.5) [879.0]	876 (173.8) [811.0]

SD=Standard deviation

## Results Algorithm Performance

- In the pairwise correlation analysis, a total of 4 variables were removed (Table 1, variables in blue).
- The candidate algorithm with hemophilia A treatments included: FVIII prophylaxis ( $\geq 50$  units of FVIII/kg/week for 45 weeks/year) OR emicizumab use OR central venous catheter placement/removal
  - Resulted in 92.5% sensitivity, 66.0% specificity, 75.4% PPV, and 88.6% NPV (Table 3).
- The candidate algorithm without hemophilia A treatments included: symptoms of hemophilia A (non-traumatic intracranial hemorrhage OR arthropathy OR hemarthrosis) OR treatments for symptoms ( $\geq 2$  joint replacements OR  $\geq 10$  physical therapy visits OR  $\geq 90$ -day opioid supply OR  $\geq 2$  COX-2 inhibitor prescriptions)
  - Resulted in 52.8% sensitivity, 70.2% specificity, 66.7% PPV, and 56.9% NPV (Table 3).

Table 3. High-Performing Concept Groups

Concept Groups	Sensitivity	PPV	Specificity	NPV
With hemophilia A treatment Treatments of hemophilia and no DDAVP <sup>1</sup>	92.5%	75.4%	66.0%	88.6%
Without hemophilia A treatment Symptoms of hemophilia OR treatments for symptoms, and no DDAVP <sup>2</sup>	52.8%	66.7%	70.2%	56.9%

DDAVP=Intravenous or intranasal desmopressin, PPV=positive predictive value, NPV=negative predictive value

<sup>1</sup>Included FVIII prophylaxis ( $\geq 50$  units of FVIII/kg/week for 45 weeks in 1 year) OR emicizumab use OR central venous catheter placement/removal.

<sup>2</sup>Includes symptoms of hemophilia (non-traumatic intracranial hemorrhage OR arthropathy OR hemarthrosis) OR treatments for symptoms ( $\geq 2$  joint replacements OR  $\geq 10$  physical therapy visits OR  $\geq 90$ -day opioid supply OR  $\geq 2$  COX-2 inhibitor prescriptions).

## Conclusions

- We developed evidence-based algorithms informed by clinicians and tested the performance of these algorithms in medical records. Using this methodology helps the algorithms resonate clinically to future users, such as clinicians, researchers, and payers.
- The algorithm with hemophilia A treatments demonstrated satisfactory sensitivity and specificity, increasing confidence in its ability to identify patients with severe hemophilia A in healthcare claims, with expected weight potentially being a suitable proxy for use in healthcare claims. We expect algorithm performance to be better in a real-world random sample of patients (compared to our purposive study sample).
- This algorithm will help improve estimates of disease burden and healthcare utilization of patients with severe hemophilia A by allowing researchers to use healthcare claims datasets to identify these patients.
- Future research should focus on developing a satisfactory algorithm without hemophilia A treatments as the treatment landscape continues to evolve.

Presented at ISPOR 2022 | 15–18 May